U.S. markets closed
  • S&P Futures

    3,886.25
    +12.75 (+0.33%)
     
  • Dow Futures

    31,547.00
    +81.00 (+0.26%)
     
  • Nasdaq Futures

    13,298.75
    +74.50 (+0.56%)
     
  • Russell 2000 Futures

    2,260.90
    +10.80 (+0.48%)
     
  • Crude Oil

    61.69
    +0.20 (+0.33%)
     
  • Gold

    1,814.90
    +6.50 (+0.36%)
     
  • Silver

    28.35
    +0.27 (+0.96%)
     
  • EUR/USD

    1.2171
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.3700
    +0.0250 (+1.86%)
     
  • Vix

    23.45
    +1.40 (+6.35%)
     
  • GBP/USD

    1.4074
    +0.0010 (+0.07%)
     
  • USD/JPY

    105.0110
    -0.0420 (-0.04%)
     
  • BTC-USD

    52,034.71
    -4,713.28 (-8.31%)
     
  • CMC Crypto 200

    1,041.92
    -89.41 (-7.90%)
     
  • FTSE 100

    6,612.24
    -11.78 (-0.18%)
     
  • Nikkei 225

    30,156.03
    +138.11 (+0.46%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PEN, AZN and EH

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / February 22, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Penumbra, Inc. (NYSE:PEN)
Class Period: August 3, 2020 - December 15, 2020
Lead Plaintiff Deadline: March 16, 2021

Penumbra, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) that the Jet 7 Xtra Flex had known design defects that made it unsafe for its normal use; (2) that Penumbra did not adequately address the risk of the Jet 7 Xtra Flex causing serious injury and deaths, which had in fact already occurred; (3) that the Jet 7 Xtra Flex was likely to be recalled due to its safety issues; and (4) as a result, Penumbra's public statements as set forth above were materially false and misleading at all relevant times.

Learn about your recoverable losses in PEN: http://www.kleinstocklaw.com/pslra-1/penumbra-inc-loss-submission-form?id=13063&from=1

Astrazeneca Plc (NYSE:AZN)
Class Period: May 21, 2020 - November 20, 2020
Lead Plaintiff Deadline: March 29, 2021

The complaint alleges that during the class period Astrazeneca Plc made materially false and/or misleading statements and/or failed to disclose that: (a) initial clinical trials for the Company's COVID-19 vaccine, AZD1222, had suffered from a critical manufacturing error, resulting in a substantial number of trial participants receiving half the designed dosage; (b) clinical trials for AZD1222 consisted of a patchwork of disparate patient subgroups, each with subtly different treatments, undermining the validity and import of the conclusions that could be drawn from the clinical data across these disparate patient populations; (c) certain clinical trial participants for AZD1222 had not received a second dose at the designated time points, but rather received the second dose up to several weeks after the dose had been scheduled to be delivered according to the original trial design; (d) AstraZeneca had failed to include a substantial number of patients over 55 years of age in its clinical trials for AZD1222, despite this patient population being particularly vulnerable to the effects of COVID-19 and thus a high priority target market for the drug; (e) AstraZeneca's clinical trials for AZD1222 had been hamstrung by widespread flaws in design, errors in execution, and a failure to properly coordinate and communicate with regulatory authorities and the general public; (f) as a result of (a)-(e) above, the clinical trials for AZD1222 had not been conducted in accordance with industry best practices and acceptable standards and the data and conclusions that could be derived from the clinical trials was of limited utility; and (g) as a result of (a)-(f) above, AZD1222 was unlikely to be approved for commercial use in the United States in the short term, one of the largest potential markets for the drug.

Learn about your recoverable losses in AZN: http://www.kleinstocklaw.com/pslra-1/astrazeneca-plc-loss-submission-form?id=13063&from=1

Ehang Holdings Limited (NASDAQ:EH)
Class Period: December 12, 2019 - February 16, 2021
Lead Plaintiff Deadline: April 19, 2021

During the class period, Ehang Holdings Limited allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's purported regulatory approvals in Europe and North American for its EH216 were for use as a drone, and not for carrying passengers; (ii) its relationship with its purported primary customer is a sham; (iii) EHang
has only collected on a fraction of its reported sales since its ADS began trading on NASDAQ in December 2019; (iv) the Company's manufacturing facilities were practically empty and lacked evidence of advanced manufacturing equipment or employees; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in EH: http://www.kleinstocklaw.com/pslra-1/ehang-holdings-limited-loss-submission-form?id=13063&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/631240/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-PEN-AZN-and-EH